X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
HC-7366, a selective activator of the general control nonderepressible 2 kinases in combination with Welireg (belzutifan), Merck’s oral HIF-2α inhibitor is being investigated for the treatment of clear cell renal cell carcinoma.
Lead Product(s): HC-7366,Belzutifan
Therapeutic Area: Oncology Product Name: HC-7366
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 01, 2024
Details:
The collaboration aims to evaluate HiberCell's HC-7366, a selective activator of the general control nonderepressible 2 kinases in combination with Welireg (belzutifan), Merck’s oral HIF-2α inhibitor for the treatment of clear cell renal cell carcinoma.
Lead Product(s): HC-7366,Belzutifan
Therapeutic Area: Oncology Product Name: HC-7366
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Merck & Co
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration December 05, 2023
Details:
HC-5404 is a first-in-class, first-in-human selective and potent PKR-like endoplasmic reticulum kinase (PERK) inhibitor. Itis being evaluated in phase 1 clinical trials for the treatment of solid tumors.
Lead Product(s): HC-5404
Therapeutic Area: Oncology Product Name: HC-5404
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 27, 2023
Details:
Imprime PGG (odetiglucan) is a pathogen-associated molecular pattern which is designed to enhance innate immune functions, including cytotoxic effector mechanisms, to reverse immunosuppression and facilitate cross-talk with the adaptive immune system.
Lead Product(s): Odetiglucan,CDX-1140
Therapeutic Area: Oncology Product Name: Imprime PGG
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Celldex Therapeutics
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 22, 2023
Details:
HC-7366, a first-in-class, first-in-human GCN2 activator. In preclinical studies, HC-7366 was observed to have robust anti-tumor and immunomodulatory activity in a variety of models of solid tumors and hematological malignancies.
Lead Product(s): HC-7366
Therapeutic Area: Oncology Product Name: HC-7366
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 22, 2023
Details:
The posters will present the immunomodulatory mechanisms of HC-7366, a differentiated selective, orally bioavailable activator of GCN2 (general controlled nonderepressible 2). HiberCell is currently conducting Phase 1 clinical trials in solid tumors for HC-7366.
Lead Product(s): HC-7366
Therapeutic Area: Oncology Product Name: HC-7366
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 02, 2022
Details:
Imprime PGG (odetiglucan) is a pathogen-associated molecular pattern which is designed to enhance innate immune functions, including cytotoxic effector mechanisms, to reverse immunosuppression and facilitate cross-talk with the adaptive immune system.
Lead Product(s): Odetiglucan,Pembrolizumab
Therapeutic Area: Oncology Product Name: Imprime PGG
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 24, 2022
Details:
Odetiglucan, a novel intravenously administered investigational innate and adaptive immune modulator, has previously been investigated in combination with pembrolizumab in immune checkpoint inhibitor-naive metastatic triple negative breast cancer patients.
Lead Product(s): Odetiglucan,Pembrolizumab
Therapeutic Area: Oncology Product Name: Imprime PGG
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 28, 2022
Details:
Odetiglucan or Imprime PGG, a Dectin-1, pattern recognition receptor agonist, is currently in phase 2 clinical trial in combination with pembrolizumab, an anti-programmed death receptor-1 therapy used in cancer immunotherapy, for treatment of metastatic breast cancer.
Lead Product(s): Odetiglucan,Pembrolizumab
Therapeutic Area: Oncology Product Name: BTH-1677
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Imprime PGG
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 03, 2022
Details:
The first-in-human Phase 1a/b clinical trial, designed to establish maximum tolerated dose, while evaluating safety and tolerability, and to establish recommended Phase 2 dose for HC-7366, selective, orally bioavailable modulator of GNC2 in patients with advanced solid tumors.
Lead Product(s): HC-7366-K
Therapeutic Area: Oncology Product Name: HC-7366
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Labcorp Drug Development
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 24, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
